Characteristics and outcomes of patients with CLL and CDKN2A/B deletion by fluorescence in situ hybridization

Blood Adv. 2023 Dec 12;7(23):7239-7242. doi: 10.1182/bloodadvances.2023010753.

Affiliations

¹ Division of Hematology, Comprehensive Cancer Center, The Ohio State University, Columbus, OH.
² Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH.
³ Department of Pathology, The Ohio State University, Columbus, OH.
⁴ Department of Internal Medicine, The University of Cincinnati, Cincinnati, OH.

No abstract available

MeSH terms

Chromosome Deletion
Cyclin-Dependent Kinase Inhibitor p16 / genetics
Gene Deletion
Humans
In Situ Hybridization, Fluorescence
Leukemia, Lymphocytic, Chronic, B-Cell* / diagnosis
Leukemia, Lymphocytic, Chronic, B-Cell* / genetics

Substances

CDKN2A protein, human
Cyclin-Dependent Kinase Inhibitor p16

Grants and funding

R01 CA177292/CA/NCI NIH HHS/United States